In a nutshell
This study aimed to investigate the GIMEMA LAL-1308 treatment protocol in young patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
This study concluded that this treatment protocol was safe and effective for these patients.
Adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) are a unique patient population with specific characteristics. Evidence suggests that children-based treatments may improve the outcome for these patients.
The GIMEMA LAL-1308 protocol involves 7 days of prednisone (Deltasone), followed by a methotrexate (Otrexup) injection into the spinal canal. This is followed by IA induction (vincristine, daunorubicin, prednisone, and asparaginase) and IB consolidation (cyclophosphamide, standard-dose cytarabine, and 6-mercaptopurine).
It was unknown if the GIMEMA LAL-1308 treatment protocol would be safe and effective in AYA with Philadelphia chromosome-negative (Ph-) ALL.
Methods & findings
This study involved 76 AYA patients aged 18 to 35 with Ph- ALL. They received the GIMEMA LAL-1308 treatment protocol.
At the end of the IA phase, 90.7% had achieved a complete response (CR). 73 patients proceeded to the IB consolidation treatment. The complete response (CR) rate was 92% after the IB phase.
24 patients relapsed after an average of 16 months. After 4 years, 60.3% of patients were alive and 60.4% were alive without signs of cancer. There were no significant differences in survival without signs of cancer between patients with standard-risk ALL and those with high-risk ALL.
The bottom line
This study concluded that the pediatric-inspired GIMEMA LAL-1308 treatment protocol is safe and effective in AYA patients with Ph- ALL.
The fine print
This study had a small number of participants. Some patients were lost to follow-up. This might have influenced the results.
Published By :
American Journal of Hematology
Dec 07, 2020